Mindfulness-Based Relapse Prevention with Individuals Receiving Medication-Assisted Outpatient Treatment for Opioid Use Disorder
The effectiveness of Mindfulness-Based Relapse Prevention (MBRP) in a naturalistic outpatient setting for those in recovery from opioid use disorder receiving medication-assisted treatment is unknown. The purpose of this pilot study was to test the effectiveness of MBRP in a naturalistic outpatient setting for those in recovery from opioid use disorder. Participants were recruited from a comprehensive opioid addiction treatment program who were in the intermediate stage of medication-assisted treatment (MAT) (at least 90 consecutive days substance free). Participants who completed the MBRP intervention served as their own controls [i.e., each participant participated in 8 weeks of treatment-as-usual (TAU) with MAT before the 8-week MBRP was initiated]. Pre/post-data analysis with study completers and non-completers (i.e., participants who did not complete the mindfulness intervention, but remained in TAU) was performed. Thirty-two participants were recruited (mean age, 36; range 21–47). No significant differences in baseline demographics were detected between the completers and non-completers. Analyses suggest significant reductions (p < 0.05) were observed in reported depression in completers compared to non-completers, and significant increases were observed in reported mindfulness (p < 0.05) in completers among those completed the MBRP intervention study phase. Trends in the hypothesized direction were also observed for anxiety (p = 0.17), but not for craving (p = 0.43). Although significant attrition was experienced, results suggest MBRP can be incorporated into a MAT in an outpatient setting, and significant positive findings were observed despite the small sample size. An unexpected finding was that patients in MAT still reported clinically significant levels of anxiety and depression that were not reduced in TAU.
KeywordsMindfulness-Based Relapse Prevention Medication-assisted treatment Outpatient treatment Opioid use disorder
Supported/provided by internal funding from West Virginia University Department of Behavioral Medicine and Psychiatry.
KJZ led all aspects of the study, including writing of the article, and data analyses. LRL helped conceive the study, led study recruitment efforts, and provided input into the article. SS coordinated study recruitment and data collection efforts and provided input into the article. MRB co-led MBRP sessions with participants and edited and provided input into the article. GRH provided statistical support and input into the article. LF co-led MBRP sessions with participants and provided input into the article.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- Bowen, S., Witkiewitz, K., Clifasefi, S. L., Grow, G., Chawla, N., Hsu, S. H., Carroll, H. A., Harrop, E., Collins, S. E., Lustyk, M. K., & Larimer, M. E. (2014). Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: a randomized clinical trial. JAMA Psychiatry, 71(5), 547–556.CrossRefPubMedPubMedCentralGoogle Scholar
- Campbell-Sills, L., Norman, S. B., Craske, M. G., Sullivan, G., Lang, A. J., Chavira, D. A., Bystritsky, A., Sherbourne, C., Roy-Byrne, P., & Stein, M. B. (2009). Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). Journal of Affective Disorders, 112(1–3), 92–101.CrossRefPubMedGoogle Scholar
- Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health (HHS) Publication No. SMA 15-4927, NSDUH Series H-50. http://www.samhsa.gov/data/. Accessed 22 December 2016.
- Centers for Disease Control and Prevention (CDC), National Center for Health Statistics.Multiple Cause of Death 1999–2014 on CDC WONDER Online. Database. (2015). Data are from the multiple cause of death files, 1999–2014, as compiled from data provided by the 57 vital statistics jurisdictions through the vital statistics cooperative program. http://wonder.cdc.gov/mcd-icd10.html. Accessed 4 January 2017.
- Eisendrath, S. J., Gillung, E., Delucchi, K. L., Segal, Z. V., Nelson, J. C., McInnes, L. A., Mathalon, D. H., & Feldman, M. D. (2016). A randomized controlled trial of mindfulness-based cognitive therapy for treatment-resistant depression. Psychotherapie Psychosomatik, medizinische, Psychologie, 85(2), 99–110.CrossRefGoogle Scholar
- Ferszt, G. G., Miller, R. J., Hickey, J. E., Maull, F., & Crisp, K. (2015). The impact of a mindfulness based program on perceived stress, anxiety, depression and sleep of incarcerated women. International Journal of Environmental. Research and Public Health, 12(9), 11594–11607.CrossRefPubMedPubMedCentralGoogle Scholar
- Gwilliam, M. (2013). West Virginia behavioral health epidemiological profile. Charleston: West Virginia Department of Health and Human Resources, Bureau for Behavioral Health and Health Facilities, Division on Alcoholism and Drug Abuse.Google Scholar
- Levi, J., Segal, L. M., & Martin, A. (2015). The facts hurt: a state-by-state injury prevention policy report. Trust for Americas Health and the Robert Wood Johnson Foundation.Google Scholar
- Mattick, R.P., Breen C., Kimber, J., & Davoli M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2, No. CD002207.Google Scholar
- McLellan, A. T., & McKay, J. (1998). The treatment of addiction: what can research offer practice? In S. Lamb, M. Greenlick, & D. McCarty (Eds.), Bridging the gap: forging new partnerships in community-based drug abuse treatment. Washington, DC: National Academy Press.Google Scholar
- Sobell, L. C., & Sobell, M. B. (1996). Timeline Followback user’s guide: a calendar method for assessing alcohol and drug use. Toronto: Addiction Research Foundation.Google Scholar
- Woody, G. E., Bruce, D., Korthuis, P. T., Chhatre, S., Poole, S., Hillhouse, M., Jacobs, P., Sorensen, J., Saxon, A. J., Metzger, D., & Ling, W. (2014). HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. Journal of Acquired Immune Deficiency Syndromes, 66(3), 288–293.CrossRefPubMedPubMedCentralGoogle Scholar